CHMP positive for Tauvid (flortaucipir F 18) intended for the diagnosis of Alzheimer’s disease,- Eli Lilly.
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tauvid, intended for the diagnosis of Alzheimer’s disease. The applicant for this medicinal product is Eli Lilly Nederland B.V.
Tauvid will be available as a solution for injection (800 MBq/ml and 1900 MBq/ml). The active substance of Tauvid is flortaucipir (18F), a diagnostic radiopharmaceutical for the central nervous system (ATC code: V09AX07). Flortaucipir binds to aggregated tau protein enabling brain positron emission tomography (PET) imaging. The benefit of Tauvid is its potential to improve the diagnosis of Alzheimer’s disease, as supported by a histopathology study. The most common side effects are headache, injection site pain and increased blood pressure.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.